Pregnenolone Sulfate an Early Marker of the Memory Loss in Alzheimer's Disease (STERMEM)
The steroid pregnenolone sulfate (PREGS) may be one of the factors responsible for the memory decline related to normal aging or associated with Alzheimer's disease (AD). The purpose of this study is to determine whether plasma levels of PREGS are decreased patients with at mild to moderate AD compared with AD-free control subjects matched for gender and age and to see whether they are inversely correlated with the severity of memory deficits in AD patients. The hypothesis is that blood levels of PREGS are decreased with advanced age and with the stage of AD that would be positively correlated with memory deficits. Therefore PREGS could be considered as an early marker of the memory deficits in AD.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Neuroactive Steroids and Cognition in Humans: Pregnenolone Sulfate an Early Marker of the Memory Loss Associated With Alzheimer's Disease|
- Plasma concentrations of PREGS determined by GC-MS [ Time Frame: At the day of diagnostic blood collection ] [ Designated as safety issue: No ]
- Memory scores of the RL-RI test according to the GROBER and BUSCKE test [ Time Frame: At the day of blood collection ] [ Designated as safety issue: No ]
- Plasma concentrations of PREGS metabolites [ Time Frame: At the day of blood collection ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Plasma and serum from AD patients and from Controls
|Study Start Date:||September 2009|
|Study Completion Date:||September 2011|
|Primary Completion Date:||September 2011 (Final data collection date for primary outcome measure)|
Patients with early and moderate AD
AD free volunteer-controls matched for gender and age
PREGS is a derivative of pregnenolone which the obligatory precursor of all steroid hormones originating from the gonads and adrenal glands. In rodents, PREGS has been demonstrated to improve memory performance in various behavioural tests. In humans, PREGS is one the most abundant circulating steroids. There are some indications about its decrease in blood during aging, and in brain samples from aged patients with AD, low concentrations of PREGS have been correlated with high levels of beta-amyloid peptide and phosphorylated tau protein. To date, a precise and rigorous evaluation of PREGS blood concentrations during aging is lacking and the relationship between these concentrations and the memory loss associated with AD has not been established.
Primary objective To show that plasma concentrations of PREGS are decreased in AD patients (" case ") compared to free-AD subjects (" controls "), matched for gender and age.
- To show that plasma concentrations of PREGS are inversely correlated with the severity of memory deficits in AD patients.
- To show that plasma concentrations of PREGS are correlated with the memory scores in the controls.
- To show that plasma concentrations of PREGS decrease in the controls.
- To search for a relationship between some of PREGS metabolites and age or the severity of memory deficits.
This is a case-control study that will comprise 200 subjects aged over 70 years, including 100 outpatients with mild to moderate AD and 100 AD-free volunteer controls matched on age and gender. These two groups will be stratified into age-sub-groups [70-74] [75-79] [80-84] [85-89] > 90 years and will include 10 men and 10 women per sub-group.
AD patients and controls will be enrolled and evaluated in the geriatric centres of 5 hospitals namely BICETRE, BROCA, PAUL BROUSSE, PITIE-SALPETRIERE and ROTHSCHILD. They will all be submitted to a clinical examination, biological analyses, cognitive tests and a brain magnetic resonance imaging scan. Blood will be collected from all subjects for steroid analysis by gas chromatography-mass spectrometry, a sensitive and accurate methodology that allows simultaneous quantification of several steroids in the same individual sample. PREGS and some of its metabolites will be identified and quantified at the "Institute medical of heath" (INSERM U788).
Please refer to this study by its ClinicalTrials.gov identifier: NCT00912886
|Assistance publique - Hôpitaux de Paris Hôpital Bicêtre|
|Le Kremlin Bicêtre, France, 94275|
|Inserm Umr 788|
|Le Kremlin Bicêtre, France, 94276|
|AP-HP Hôpital Rothschild|
|Paris, France, 75012|
|Assistance Publique - Hôpitaux de Paris Hôpital Broca|
|Paris, France, 75013|
|Assistance Publique - Hôpitaux de Paris, Hôpital Pitié-Salpétrière|
|Paris, France, 75013|
|Assistance Publique - Hôpitaux de Paris, Hôpital Paul Brousse|
|Villejuif, France, 94800|
|Principal Investigator:||Sebastien Weill-Engerer, MD||Assistance Publique - Hôpitaux de Paris Hôpital Rothschild|
|Study Director:||Yvette Akwa, PhD||INSERM U788|